Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

10.7%

3 terminated/withdrawn out of 28 trials

Success Rate

89.3%

+2.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

5 of 25 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1
28(100.0%)
28Total
Phase 1(28)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials
NCT02627625Phase 1Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products

Role: collaborator

NCT02676297Phase 1Completed

Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products

Role: collaborator

NCT03237741Phase 1Completed

Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants

Role: collaborator

NCT02604914Phase 1Completed

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

Role: collaborator

NCT02557139Phase 1Completed

Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

Role: collaborator

NCT03266172Phase 1Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Role: collaborator

NCT04585347Phase 1Completed

Single Dose Study of ALZ-801 Prototype Tablets

Role: collaborator

NCT04157712Phase 1Completed

Multiple Ascending Dose Study of ALZ-801

Role: collaborator

NCT02912026Phase 1Withdrawn

Radiolabelled IV and Oral Metabolism Study of F901318

Role: collaborator

NCT03240445Phase 1Completed

Impact of Changing the Dosing Regimen on the PK Profile of ODM-203

Role: collaborator

NCT02720224Phase 1Completed

Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol

Role: collaborator

NCT03397641Phase 1Completed

A Phase 1 Study of HBI-3000

Role: collaborator

NCT03131141Phase 1Completed

A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781

Role: collaborator

NCT02998190Phase 1Completed

First-in-Human Single and Multiple Dose of EB8018

Role: collaborator

NCT03067363Phase 1Terminated

First in Human Single Ascending Dose Study of MOR107

Role: collaborator

NCT03076905Phase 1Withdrawn

Pharmacokinetics of IV Formulation

Role: collaborator

NCT02521389Phase 1Completed

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143

Role: collaborator

NCT03185195Phase 1Completed

Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125

Role: collaborator

NCT02808741Phase 1Completed

Evaluation of Immediate Release Tablet

Role: collaborator

NCT02710188Phase 1Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Role: collaborator